Gilead Sciences, Inc. (BMV:GILD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 3.98T +47.1% |
| Revenue (ttm) | 558.55B +6.5% |
| Net Income | -69.61B |
| EPS | -58.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 21.57 |
| Dividend | 58.18 (1.80%) |
| Ex-Dividend Date | Dec 15, 2026 |
| Volume | 879 |
| Open | 3,252.25 |
| Previous Close | 3,100.10 |
| Day's Range | 3,235.00 - 3,252.25 |
| 52-Week Range | 2,116.00 - 3,235.00 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare ...
Gilead price target raised to $200 from $177 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Gilead (GILD) to $200 from $177 and keeps an Outperform rating on the shares. The firm believes the price target…
Gilead price target raised to $183 from $163 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $183 from $163 and keeps an Overweight rating on the shares.
Gilead price target raised to $190 from $170 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Gilead (GILD) to $190 from $170 and keeps an Overweight rating on the shares.
Gilead price target raised to $181 from $158 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $181 from $158 and keeps a Buy rating on the shares. The company delivered a beat on…
Gilead price target raised to $175 from $160 at TD Cowen
TD Cowen analyst Tyler Van Buren raised the firm’s price target on Gilead (GILD) to $175 from $160 and keeps a Buy rating on the shares. The firm said Q3…
Gilead price target raised to $195 from $175 at UBS
UBS raised the firm’s price target on Gilead (GILD) to $195 from $175 and keeps a Buy rating on the shares. Gilead posted a strong Q3 beat and raise driven…
Gilead price target raised to $175 from $155 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps an Overweight rating on the shares. Gilead delivered its largest revenue beat since the…
Gilead price target raised to $200 from $170 at Needham
Needham raised the firm’s price target on Gilead (GILD) to $200 from $170 and keeps a Buy rating on the shares. The company’s topline Q3 beat was again highlighted by…
Gilead price target raised to $188 from $165 at Citi
Citi raised the firm’s price target on Gilead (GILD) to $188 from $165 and keeps a Buy rating on the shares. The company’s Q3 report reinforced confidence in the durability…
Gilead price target raised to $190 from $165 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $190 from $165 and keeps an Overweight rating on the shares. The firm thinks Gilead’s Q3…
Gilead Sciences Earnings Call Transcript: Q3 2026
Base business sales rose 16% YoY to $8.2B, the strongest growth in more than a decade, prompting higher FY2026 guidance. Strong HIV, TRODELVY and Livdelzi results were tempered by cell therapy competition and a projected ~$1.5B 2028 BIKTARVY pricing impact.
Gilead Sciences Earnings release: Q3 2026
Gilead Sciences released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Gilead Sciences Slides: Q3 2026
Gilead Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Gilead Sciences Prepared remarks: Q3 2026
Gilead Sciences filed a regulatory document on October 29, 2026 disclosing important business information.
Gilead Sciences Quarterly report: Q3 2026
Gilead Sciences has published its Q3 2026 quarterly earnings report on October 29, 2026.
Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
The biopharmaceutical company said it now expects full-year product sales of $31 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.
Gilead reports Q3 adjusted EPS $2.55, consensus $1.78
Reports Q3 revenue $8.3B, consensus $7.8B. “Gilead (GILD) delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength,...
Gilead's HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress.
Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line.
Gilead Sciences Announces Third Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026. “Gilead delivered an exceptional third quar...
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme
HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporti...
Gilead to acquire IL-23R inhibitor program from PepStar Therapeutics
Gilead (GILD) Sciences announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a priva...
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead a...
Texas AG secures $45M settlement with Gilead
Texas Attorney General Ken Paxton secured $45M in a settlement with Gilead (GILD) Sciences to resolve claims that the company engaged in an illegal kickback scheme that improperly influenced prescript...
Gilead to present new clinical, real-world evidence across PBC, HDV
Gilead (GILD) Sciences will present new clinical and real-world evidence across primary biliary cholangitis, PBC, and chronic hepatitis delta virus, HDV, infection at The Liver Meeting 2026, hosted by...